Grufity logo
Grufity logo
KRYS

KRYS - Krystal Biotech Inc Stock Price, Fair Value and News

$364.23+12.41 (+3.53%)
Market Closed as of 28 Jul 2026, 04:00 pm ET

67/100

KRYS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

67/100

KRYS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

KRYS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KRYS Price Action

Last 7 days

7.4%

Last 30 days

-2.1%

Last 90 days

40.1%

Trailing 12 Months

138.2%

KRYS RSI Chart

KRYS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

KRYS Valuation

Market Cap

10.7B

Price/Earnings (Trailing)

47.72

Price/Sales (Trailing)

25.73

EV/EBITDA

48.04

Price/Free Cashflow

45.23

KRYS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

KRYS Fundamentals

KRYS Revenue

Revenue (TTM)

417.3M

Rev. Growth (Yr)

31.95%

Rev. Growth (Qtr)

8.64%

KRYS Earnings

Earnings (TTM)

225.0M

Earnings Growth (Yr)

56.53%

Earnings Growth (Qtr)

8.82%

KRYS Profitability

EBT Margin

49.68%

Return on Equity

17.63%

Return on Assets

16.11%

Free Cashflow Yield

2.21%

KRYS Investor Care

Shares Dilution (1Y)

2.31%

Diluted EPS (TTM)

7.48

KRYS Alerts

  • 1 major insider sales recently.
Revenue & Growth

How Krystal Biotech Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026417.3M---
2025333.4M359.2M373.2M389.1M
2024108.5M166.2M241.5M290.5M
2023---50.7M
2022----
2021----
2020----
2019----
2018----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Krystal Biotech Inc

KRYS
Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
 CEO
 WEBSITEkrystalbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES210

Krystal Biotech Inc Frequently Asked Questions

KRYS is the stock ticker symbol of Krystal Biotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jul 28 2026, market cap of Krystal Biotech Inc is 10.74 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Tue Jul 28 2026, KRYS's PE ratio (Price to Earnings) is 47.72 and Price to Sales (PS) ratio is 25.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KRYS PE ratio will change depending on the future growth rate expectations of investors.